Expression of MiR-592 in Breast Cancer and Its Correlation with Clinicopathology
Objective:To investigate the expression of microRNA(miR)-592 in breast cancer and its correlation with clinicopathology.Methods:70 patients with breast cancer admitted to our hospital from January 2018 to December 2019 were selected,and their breast cancer tissues and adjacent tissues were taken for immunohistochemical detection to detect the expression level of miR-592.The expression level of miR-592 in breast cancer patients with different clinicopathological characteristics was analyzed,and the correlation between miR-592 and breast cancer clinicopathology was analyzed by Spearman correlation.All patients were followed up for 4 years to record the total survival time of breast cancer patients and analyze the relationship between miR-592 and the survival time of breast cancer patients.Results:The relative expression and positive rate of miR-592 in breast cancer tissues were significantly lower than those in adjacent tissues(P<0.05);There was no significant difference in the relative expression level of miR-592 among different ages,histological types,tumor sizes,and tissue differentiation levels(P>0.05),while there was a significant difference in the relative expression level of miR-592 among different clinical stages and lymph node metastases(P<0.05);Spearman correlation analysis showed that miR-592 was negative correlated with clinical stage and lymph node metastasis of breast cancer(P<0.05);After a 4-year follow-up,the median overall survival time of patients with high miR-592 was 40.37(18.47 to 60.00)months,which was significantly higher than the median overall survival time of 30.57(13.57 to 60.00)months.Conclusion:The low expression of miR-592 in breast cancer is related to the clinical stage and lymph node metastasis of breast cancer,and the low expression of miR-592 may mean poor prognosis of breast cancer patients.